- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00038714
A Trial Study of SGN-00101 in Treating Pediatric Patients With Recurrent Respiratory Papillomatosis
June 26, 2007 updated by: Nventa Biopharmaceuticals Corporation
A Phase II Trial of SGN-00101 In The Treatment of Pediatric Recurrent Respiratory Papillomatosis
Recurrent Respiratory Papillomatosis (RRP) causes wart-like lesions along the throat area and can obstruct the airway or become malignant.
The cause has been related to specific types of Human Papillomavirus (HPV).
The purpose of the study is to assess the clinical effectiveness of a trial drug, SGN-00101, in children with RRP and also assess its safety.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
27
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35233
- Children's Hospital of Alabama
-
-
Arkansas
-
Little Rock, Arkansas, United States, 72202
- University of Arkansas for Medical Sciences, Arkansas Children's Hospital
-
-
Florida
-
Jacksonville, Florida, United States, 32207
- Nemour's Childrens Clinic, Division of Pediatric Oncology
-
-
Iowa
-
Iowa City, Iowa, United States, 52242
- University of Iowa Hospitals and Clinics
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55455
- Fairview University Medical Center, University of Minnesota
-
-
Ohio
-
Cleveland, Ohio, United States, 44106
- University Hospitals of Cleveland
-
-
Texas
-
Dallas, Texas, United States, 75390
- University of Texas, Southwestern Medical School
-
-
Virginia
-
Norfolk, Virginia, United States, 23507
- Children's Hospital of The King's Daughters
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
2 years to 18 years (Child, Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or female between 2 and 18 yrs old, inclusive, who has documented RRP.
- Patients with documented RRP
- Subject is surgically debulked within 7 days before the first dose of SGN-00101.
- Subject has had at least 4 debulking surgeries for RRP, had no intersurgical intervals greater than 84 days during the period of the last 4 surgeries.
- Subject is free of life threatening or serious concomitant disorders other than the disease under study.
- Females of childbearing potential must have a negative pregnancy test and must be practicing an effective/appropriate method of birth control as determined by the Investigator.
Exclusion Criteria:
- Subject has disease or status that causes compromise of the immune system.
- Subject has a history of ionizing radiation therapy to the respiratory tract.
- Patient has used concomitant medications that may suppress the immune system.
- Subject has received any specific or non-specific immunotherapy intended as treatment for their RRP (i.e. mumps vaccine injected intralesionally) within 9 months prior to Week 0 of this study.
- Subject has participated in a past study with SGN-00101
- Pregnancy and lactation.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2001
Study Completion
January 1, 2004
Study Registration Dates
First Submitted
June 4, 2002
First Submitted That Met QC Criteria
June 4, 2002
First Posted (Estimate)
June 5, 2002
Study Record Updates
Last Update Posted (Estimate)
June 27, 2007
Last Update Submitted That Met QC Criteria
June 26, 2007
Last Verified
June 1, 2007
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Virus Diseases
- Infections
- Respiratory Tract Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms, Glandular and Epithelial
- Disease Attributes
- DNA Virus Infections
- Tumor Virus Infections
- Neoplasms, Squamous Cell
- Recurrence
- Respiratory Tract Infections
- Papillomavirus Infections
- Papilloma
Other Study ID Numbers
- Stressgen SGN-00101-0005
- SGN-00101-0005
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Papilloma
-
University Medical Center GroningenActive, not recruitingInverted Papilloma | Molecular Fluorescence ImagingNetherlands
-
Beijing Tongren HospitalRecruitingInverted Papilloma | Draf III Procedure | Naso-septal FlapChina
-
Dana-Farber Cancer InstituteActive, not recruitingFlat Epithelia Atypia | Intraductal Papilloma Without AtypiaUnited States
-
Procare Health Iberia S.L.Adknoma Health ResearchCompletedHuman Papilloma Virus Infection | Human Papilloma Virus | Cervix LesionSpain
-
Procare Health Iberia S.L.Adknoma Health ResearchActive, not recruitingHuman Papilloma Virus Infection | Human Papilloma Virus | Cervix LesionSpain
-
Emory UniversityNational Institute of Nursing Research (NINR)RecruitingHuman Papilloma Virus | Human Papilloma Virus VaccineUnited States
-
UNC Lineberger Comprehensive Cancer CenterNational Cancer Institute (NCI)Recruiting
-
Groupe Hospitalier Paris Saint JosephRecruitingHuman Papilloma VirusFrance
-
University of VirginiaCompleted
-
Oregon Health and Science UniversityAmerican Cancer Society, Inc.; University of Arkansas; Oregon Health AuthorityActive, not recruitingHuman Papilloma VirusUnited States
Clinical Trials on SGN-00101
-
Albert Einstein College of MedicineNational Cancer Institute (NCI)CompletedCervical Cancer | Precancerous ConditionUnited States
-
National Cancer Institute (NCI)CompletedCervical Cancer | High-grade Squamous Intraepithelial Lesion | Atypical Squamous Cells of Undetermined Significance | Low-grade Squamous Intraepithelial LesionUnited States
-
National Cancer Institute (NCI)CompletedCervical Cancer | Human Papilloma Virus Infection | Cervical Intraepithelial Neoplasia Grade 3United States
-
Seagen Inc.RecruitingColorectal Neoplasms | Pancreatic Neoplasms | Mesothelioma | Non-small Cell Lung Cancer | Cutaneous MelanomaUnited States, Canada, Switzerland, France, Germany, United Kingdom
-
Seagen Inc.TerminatedUterine Cervical Neoplasms | Stomach Neoplasms | Colorectal Neoplasms | Esophageal Neoplasms | Ovarian Neoplasms | Endometrial Neoplasms | Pseudomyxoma Peritonei | Carcinoma, Non-Small Cell Lung | Gastroesophageal Junction Carcinoma | HER2 Negative Breast Neoplasms | Exocrine Pancreatic Adenocarcinoma | Appendiceal...United States, United Kingdom, Canada, Spain, France, Italy
-
Seagen Inc.RecruitingCarcinoma, Non-Small-Cell Lung | Adenoid Cystic Carcinoma | Ovarian Neoplasms | Fallopian Tube Neoplasms | Peritoneal Neoplasms | Endometrial Neoplasms | Cholangiocarcinoma | Triple Negative Breast Neoplasms | Gallbladder Carcinoma | HER2 Negative Breast Neoplasms | Hormone Receptor Positive Breast NeoplasmsUnited States, Spain, Canada, United Kingdom, Germany, Italy
-
Seagen Inc.TerminatedUterine Cervical Neoplasms | Stomach Neoplasms | Testicular Neoplasms | Carcinoma, Non-Small-Cell Lung | Ovarian Neoplasms | Endometrial Neoplasms | Gastroesophageal Junction CarcinomaUnited States, Canada, Spain, Sweden, United Kingdom
-
Seagen Inc.TerminatedColorectal Cancer | Non-small Cell Lung Cancer | Pancreatic Ductal Adenocarcinoma | Cutaneous Melanoma | Pleural Mesothelioma | HER2 Negative Breast NeoplasmsUnited States, Spain, France, Italy, United Kingdom
-
Seagen Inc.TerminatedMelanoma | Soft Tissue Sarcoma | Colorectal Cancer | Non-small Cell Lung Carcinoma | Breast Carcinoma | Head and Neck Squamous Cell Carcinoma | Gastric Carcinoma | Ovarian Carcinoma | Exocrine Pancreatic CarcinomaUnited States
-
Seagen Inc.TerminatedMultiple MyelomaUnited States